Research programme: light-activated antibody- drug conjugates - PhotoBiotics
Alternative Names: ProstaLite Photo-ImmunoConjugate; ProstaLite PICLatest Information Update: 14 Sep 2023
Price :
$50 *
At a glance
- Originator PhotoBiotics
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 14 Sep 2023 Preclinical development in Prostate cancer is ongoing United Kingdom (Antikore Innovations website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Prostate-cancer in United Kingdom (Parenteral)
- 28 Jul 2016 Research programme: light-activated antibody- drug conjugates - PhotoBiotics is available for licensing - http://www.photobiotics.com/partner-opportunities.shtml